Middle East And Africa Cancer Supportive Care Products Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2021 –2028 |
 Tamanho do mercado (ano base ) | USD 378.32 Million |
 Tamanho do mercado ( Ano de previsão) | USD 475.40 Million |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado de produtos de apoio ao cancro no Médio Oriente e em África, por tipo de medicamento (fator estimulador de colónias de granulócitos (GCSFS), agentes estimuladores de eritropoietina (ESA’S), analgésicos opióides, anticorpos monoclonais, medicamentos anti-inflamatórios não esteróides (AINEs) , bifosfonatos, antieméticos, Anti-histamínicos e outros), tipo (de marca e genéricos ), tipo de cancro ( cancro do pulmão , cancro da mama, cancro da próstata, cancro do fígado, cancro da bexiga, leucemia, melanoma, cancro da ovário e outros tipos de cancro), utilizador final ( hospitais , clínicas, hospitais e outros tipos de cancro). Instituições académicas e outros), canal de distribuição (farmácias hospitalares, farmácias de retalho e farmácias de manipulação), país (Arábia Saudita, África do Sul, Emirados Árabes Unidos, Israel, Egito e resto do Médio Oriente e África) Tendências e previsões da indústria para 2028
Análise de mercado e insights: Mercado de produtos de apoio ao cancro no Médio Oriente e em África
Espera-se que o mercado de produtos de cuidados de apoio ao cancro ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 3,0% no período de previsão de 2021 a 2028 e deverá atingir os 475,40 milhões de USD até 2028, contra 378,32 milhões de dólares em 2020.
O aumento da procura de produtos de apoio ao cancro e o aumento das iniciativas governamentais são os principais impulsionadores que impulsionam a procura do mercado no período de previsão. O mercado de produtos de apoio ao cancro ganhou grande atração nos últimos anos devido à crescente iniciativa governamental. Além disso, o aumento da incidência e prevalência de doenças cancerígenas, bem como o aumento do lançamento de produtos, também deram um impulso ao crescimento do mercado.
Os principais fatores que impulsionam o crescimento do mercado de produtos de cuidados de apoio ao cancro são o aumento da iniciação governamental para controlar a expansão do cancro e o fator que dificulta o crescimento do mercado de produtos de cuidados de apoio ao cancro são os efeitos secundários associados aos produtos de cuidados de suporte oncológico. As parcerias e aquisições dos principais players do mercado atuam como uma oportunidade para o crescimento do mercado global de produtos de apoio ao cancro.
O relatório de mercado de produtos de cuidados de apoio ao cancro fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito e dimensão do mercado de produtos de cuidados de apoio ao cancro no Médio Oriente e África
O mercado de produtos de apoio ao cancro no Médio Oriente e em África está categorizado em cinco segmentos notáveis que se baseiam no tipo de medicamento, tipo, tipo de cancro, utilizador final e canal de distribuição.
- On the basis of drug type, the cancer supportive care products market is segmented into granulocyte colony stimulating factor (GCSFs), erythropoietin stimulating agents (ESA’s), opioid analgesics, monoclonal antibodies, nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, anti-emetics, and antihistamines and others. In 2021, granulocyte colony stimulating factor (GCSFs) segment is dominating the cancer supportive care products market as it stimulates the bone marrow and generates stem cells as well as granulocytes to discharge it in bloodstream. Moreover, granulocyte colony stimulating factor (GCSFS) is primarily used to treat and cure the neutropenia caused owing to cancer chemotherapy treatment.
- On the basis of type, the cancer supportive care products market is segmented into branded and generics. In 2021, generics segment is dominating the cancer supportive care products market since it is cost effective, easily accessible and primarily recommended by doctors for cancer supportive care products diseases.
- On the basis of cancer type, the cancer supportive care products market is segmented into lung cancer, breast cancer, prostate cancer, liver cancer, bladder cancer, leukaemia, melanoma, ovarian cancer and other cancers. In 2021, the lung cancer segment is dominating the cancer supportive care products market due to growing smoking habits among populace in developed as well as developing country.
- On the basis of end user, the cancer supportive care products market is segmented into hospitals, clinics, hospitals & academic institutions and others. In 2021, hospitals segment is dominating the cancer supportive care products market as it provides patients with the best healthcare services. Moreover, hospitals are the primary healthcare service provider for patients suffering from cancer.
- On the basis of distribution channel, the cancer supportive care products market is segmented into hospital pharmacies, retail pharmacies and compounding pharmacies. In 2021, hospital pharmacies segment is dominating the cancer supportive care products market as most of the medicines are procured through hospital pharmacies. The increasing adoption of prescription based medicines, also acts as driver for the cancer supportive care products market growth.
Cancer Supportive Care Products Market Country Level Analysis
The cancer supportive care products market is analysed and market size information is provided by drug type, type, cancer type, end user and distribution channel.
The countries covered in the cancer supportive care products market report are Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa.
South Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028, in Middle East and Africa countries. The government organization and healthcare bodies are under taking various programs in this region, consequently it anticipated to propel the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Partnership and Distribution Agreement with Local Players, is Creating New Opportunities for Players in the Cancer supportive Care Products Market
Cancer supportive care products market also provides you with detailed market analysis for every country growth in cancer supportive care products product’s industry. Additionally, it provides detail information regarding growing partnership and distribution agreement with local players. The data is available for historic period 2011 to 2019.
Competitive Landscape and Cancer Supportive Care Products Market Share Analysis
Cancer supportive care products market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to cancer supportive care products market.
The major players covered in the report are Amgen Inc., Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Pfizer Inc., APR, Novartis AG, F. Hoffmann-La Roche Ltd., Acacia Pharma Group Plc., Baxter, Bayer AG, Helsinn Healthcare SA., Heron Therapeutics, Inc., Kyowa Kirin Co., Ltd., Acrotech Biopharma, Spectrum Pharmaceuticals, Inc., Oxford Pharmascience Ltd, Merck Sharp & Dohme Corp. (A Subsidiary of Merck & Co., Inc.), Teva (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Tersera Therapeutics Llc., Mylan N.V., Sun Pharmaceutical Industries Ltd., among other Middle East and Africa players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Muitas aprovações e acordos de produtos são também iniciados pelas empresas de todo o mundo, que também estão a acelerar o mercado de produtos de apoio ao cancro.
- Em janeiro de 2020, a Novartis AG declarou a aquisição da Medicines Company. Esta aquisição proporcionou uma nova oportunidade para a empresa aumentar a sua presença geográfica em todo o mundo. Além de ajudar na atualização do portfólio de produtos da empresa.
A colaboração, as joint ventures e outras estratégias do player de mercado estão a aumentar a presença da empresa no mercado de produtos de apoio ao cancro, o que também proporciona benefícios para a organização.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DRUG TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EGULATORY
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 GROWING CANCER BURDEN WORLDWIDE
5.1.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS
5.1.3 GROWING GERIATRIC POPULATION
5.1.4 RISING NUMBER OF PRODUCT APPROVAL
5.1.5 RISING EXPENDITURE ON HEALTHCARE
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER SUPPORTIVE DRUGS
5.2.2 LACK OF EARLY DETECTION
5.3 OPPORTUNITIES
5.3.1 ACQUISITION AND AGREEMENT BY MAJOR PLAYERS
5.3.2 RISING PRODUCT LAUNCHES
5.3.3 GROWING R&D ACTIVITIES
5.4 CHALLENGES
5.4.1 STRINGENT REGULATION POLICY
5.4.2 PATENT EXPIRY OF DRUGS
6 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON SUPPLY CHAIN
6.3 IMPACT ON DEMAND
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS)
7.2.1 LONG ACTING FILGRASTIM
7.2.2 FILGRASTIM
7.2.3 LENOGRASTIM
7.3 ERYTHROPOIETIN STIMULATING AGENTS (ESA’S)
7.3.1 EPO-Α/Β
7.3.2 DPO
7.3.3 CERA
7.3.4 EPO-Κ
7.4 OPIOID ANALGESICS
7.4.1 FENTANYL
7.4.2 METHADONE
7.4.3 TRAMADOL
7.4.4 OTHERS
7.5 MONOCLONAL ANTIBODIES
7.6 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
7.6.1 OTC NSAIDS
7.6.1.1 ASPIRIN
7.6.1.2 IBUPROFEN
7.6.1.3 NAPROXEN SODIUM
7.6.2 PRESCRIPTION NSAIDS
7.6.2.1 CELECOXIB
7.6.2.2 DICLOFENAC
7.6.2.3 INDOMETHACIN
7.6.2.4 KETOROLAC
7.6.2.5 MELOXICAM
7.6.2.6 NABUMETONE
7.6.2.7 NAPROXEN
7.6.2.8 OXAPROZIN
7.6.2.9 PIROXICAM
7.6.2.10 SULINDAC
7.6.2.11 OTHERS
7.7 BISPHOSPHONATES
7.7.1 ZOLEDRONIC ACID OR ZOLEDRONATE
7.7.2 DISODIUM PAMIDRONATE
7.7.3 IBANDRONIC ACID OR IBANDRONATE
7.7.4 SODIUM CLODRONATE
7.8 ANTI-EMETICS
7.8.1 APREPITANT
7.8.2 DEXAMETHASONE
7.8.3 DOLASETRON
7.8.4 GRANISETRON
7.8.5 ONDANSETRON
7.8.6 PALONOSETRON
7.8.7 PROCHLORPERAZINE
7.8.8 ROLAPITANT
7.8.9 OTHERS
7.9 ANTIHISTAMINES
7.9.1 HYDROXYZINE
7.9.2 DIPHENHYDRAMINE
7.9.3 OTHERS
7.1 OTHERS
8 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE
8.1 OVERVIEW
8.2 BRANDED
8.2.1 NEULASTA
8.2.2 ARANESP
8.2.3 PROLIA
8.2.4 XGEVA
8.2.5 EPOGEN
8.2.6 EPREX
8.2.7 NEUPOGEN
8.2.8 OTHERS
8.3 GENERICS
9 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 LUNG CANCER
9.3 BREAST CANCER
9.4 PROSTATE CANCER
9.5 LIVER CANCER
9.6 BLADDER CANCER
9.7 LEUKAEMIA
9.8 MELANOMA
9.9 OVARIAN CANCER
9.1 OTHER CANCERS
10 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.2.1 ACUTE CARE HOSPITALS
10.2.2 LONG-TERM CARE HOSPITALS
10.2.3 NURSING FACILITIES
10.3 CLINICS
10.4 HOSPITALS & ACADEMIC INSTITUTIONS
10.5 OTHERS
11 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 HOSPITAL PHARMACIES
11.3 RETAIL PHARMACIES
11.4 COMPOUNDING PHARMACIES
12 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY GEOGRAPHY
12.1 MIDDLE EAST & AFRICA
12.1.1 SOUTH AFRICA
12.1.2 SAUDI ARABIA
12.1.3 UAE
12.1.4 ISRAEL
12.1.5 EGYPT
12.1.6 REST OF MIDDLE EAST AND AFRICA
13 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
14 SWOT
15 COMPANY PROFILES
15.1 AMGEN INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 PFIZER INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOVARTIS AG
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 ACACIA PHARMA GROUP PLC
15.5.1 COMPANY SNAPSHOT
15.5.2 PRODUCT PORTFOLIO
15.5.3 RECENT DEVELOPMENTS
15.6 ACROTECH BIOPHARMA
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 APR
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 BAXTER
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 HELSINN HEALTHCARE SA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 HERON THERAPEUTICS, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 KYOWA KIRIN CO., LTD.
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 MYLAN N.V.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENTS
15.16 OXFORD PHARMASCIENCE LTD
15.16.1 COMPANY SNAPSHOT
15.16.2 TECHNOLOGY PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 SPECTRUM PHARMACEUTICALS, INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 TERSERA THERAPEUTICS LLC
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 MORTALITY DUE TO CANCER, AGES 85+, IN THE U.S.
TABLE 3 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE 2020-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE 2020-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENERICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2020-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA LUNG CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA BREAST CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PROSTATE CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA LIVER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA BLADDER CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA LEUKAEMIA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA MELANOMA IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OVARIAN CANCER IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA OTHER CANCERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA CLINICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA HOSPITALS & ACADEMIC INSTITUTIONS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA COMPOUNDING PHARMACIES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY COUNTRY 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 64 SOUTH AFRICA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 SOUTH AFRICA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 SOUTH AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 80 SAUDI ARABIA GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 96 UAE GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 97 UAE OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 98 UAE ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 UAE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 100 UAE OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 UAE PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 102 UAE BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 103 UAE ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 104 UAE ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 105 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 UAE BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 108 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 109 UAE HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 110 UAE CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 111 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 112 ISRAEL GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
TABLE 128 EGYPT GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 129 EGYPT OPIOID ANALGESICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 130 EGYPT ERYTHROPOIETIN STIMULATING AGENTS (ESA’S) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 131 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 132 EGYPT OTC NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 133 EGYPT PRESCRIPTION NSAIDS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 134 EGYPT BISPHOSPHONATES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 135 EGYPT ANTI-EMETICS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 136 EGYPT ANTIHISTAMINES IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 137 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 EGYPT BRANDED IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 139 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 140 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 141 EGYPT HOSPITALS IN CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 142 EGYPT CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 143 REST OF MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DRUG TYPE, 2019-2020 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SEGMENTATION
FIGURE 10 GROWING CANCER BUREN WORLDWIDE IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 GRANULOCYTE COLONY STIMULATING FACTOR (GCSFS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET
FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 14 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES (WORLD) IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES
FIGURE 15 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020
FIGURE 16 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, 2020-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE 2020-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020
FIGURE 24 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, 2020-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020
FIGURE 28 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 32 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: SNAPSHOT (2020)S
FIGURE 36 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2020)
FIGURE 37 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 38 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: BY TYPE (2021-2028)
FIGURE 40 MIDDLE EAST AND AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
